Lantheus Holdings, Inc. (NASDAQ:LNTH) Gains Deal Momentum Ahead Of Commercial Rollouts

Lantheus presents mixed operational strength and stretched multiple metrics, with near-term technical signals favoring consolidation as commercial catalysts approach.

Recent News

On May 21, 2026 the company received a proposed acquisition announcement that values Lantheus at an initial enterprise consideration reported publicly. On August 6, 2026 Lantheus released second-quarter 2026 financial results and hosted an earnings call summarizing performance and guidance. On July 24, 2026 the Centers for Medicare & Medicaid Services granted a HCPCS code for PYLARIFY TruVu with an effective date of October 1, 2026.

Technical Analysis

ADX / DI+ / DI-: ADX at 12.97 indicates no clear trend strength; both directional indicators point to bearish pressure—DI+ shows a peak-and-reversal (DI+ decreasing) while DI- shows a dip-and-reversal (DI- increasing)—which signals directional momentum favoring sellers relative to recent valuation levels.

MACD: MACD registers -0.75 with the signal line at -0.54 and a peak-and-reversal pattern; MACD below the signal line and declining signals bearish momentum and reduced upside follow-through near current prices.

MRO (Momentum/Regression Oscillator): MRO at 6.86 sits positive, indicating price sits above the model target and carries downward potential pressure toward that target if momentum stalls.

RSI: RSI near 49.18 and trending down shows fading short-term momentum and a bias away from sustained buying interest around present levels rather than oversold conditions.

Price vs Moving Averages and Bands: The close at $100.48 sits below the 20-day average ($100.91) and substantially below the 50-day average ($103.81), while remaining above the 200-day average ($80.71). Short-term EMAs (12-day and 26-day) decline and sit above price, reinforcing the near-term consolidation/downside tilt. Price sits marginally below the lower 1x Bollinger band, indicating compressed volatility with the potential for short-range mean reversion or continuation of the pullback to nearby cloud support (Ichimoku Senkou B at $95.93).

 


Fundamental Analysis

Earnings & Guidance Signals: Reported EPS of $1.55 beat the estimate of $1.30 by $0.25, a positive surprise of 19.23%, supporting recent operating resilience despite mixed momentum in other metrics.

Profitability: EBIT of $98,740,000 produces an EBIT margin of 25.44%, above the industry peer mean of 13.24% and above the industry peer median of 20.50%, while remaining below the industry peer high of 35.13%. Sequential dynamics show the EBIT margin declined by 40.48% quarter-over-quarter and declined 12.13% year-over-year, indicating margin compression versus the immediate prior period even as the level compares favorably to typical peers.

Revenue & Earnings Growth: Reported revenue totaled $388,180,000. YoY revenue growth reads 102.89%, while the provided revenue growth metric stands at 2.88%; sequential revenue compares poorly with a quarter-over-quarter change of -139.71%, implying strong year-on-year expansion alongside a notable sequential slowdown. Reported earnings growth registers 6.16% overall, with QoQ earnings growth down 20.81% and YoY earnings growth down 37.13%—a mixed picture of sizable annual gains offset by sequential softness.

Liquidity, Cash Flow, and Leverage: Cash and short-term investments total $593,298,000, supporting a current ratio of 3.06 and a quick ratio of 2.89, both indicating ample near-term liquidity. Free cash flow of $89,868,000 yields a free cash flow yield of 1.38%, above the industry peer mean of roughly 1.00%, though free cash flow growth shows meaningful sequential pressure. Total debt stands at $624,958,000 with debt-to-EBITDA around 5.15x; interest coverage near 20.09x suggests manageable servicing at current operating levels but the leverage multiple highlights sensitivity to operating fluctuations.

Margins & Returns: Gross margin at 62.31% and operating margin at 25.82% demonstrate durable product-level profitability. Return on equity sits near 5.72% and return on assets near 3.15%, with QoQ and YoY declines in returns consistent with the sequential margin and earnings softening noted above.

Valuation Context: Trailing P/E near 64.35 and forward P/E near 59.70, a PEG above 10, price-to-sales around 16.77 and an enterprise multiple in the 50s collectively signal elevated valuation relative to growth rates and cash return metrics. The current valuation as determined by WMDST: over-valued, reflecting stretched multiples despite solid cash reserves and high margins.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-06-30
REPORT DATE: 2026-08-06
NEXT REPORT DATE: 2026-11-05
CASH FLOW  Begin Period Cash Flow 500.3 M
 Operating Cash Flow 92.2 M
 Capital Expenditures -2.33 M
 Change In Working Capital 11.1 M
 Dividends Paid
 Cash Flow Delta 94.7 M
 End Period Cash Flow 595.0 M
 
INCOME STATEMENT REVENUE
 Total Revenue 388.2 M
 Forward Revenue 133.5 M
COSTS
 Cost Of Revenue 146.3 M
 Depreciation 22.6 M
 Depreciation and Amortization 22.6 M
 Research and Development 38.2 M
 Total Operating Expenses 288.0 M
PROFITABILITY
 Gross Profit 241.9 M
 EBITDA 121.3 M
 EBIT 98.7 M
 Operating Income 100.2 M
 Interest Income 6.3 M
 Interest Expense 4.9 M
 Net Interest Income 1.3 M
 Income Before Tax 93.8 M
 Tax Provision 18.8 M
 Tax Rate 20.033 %
 Net Income 75.0 M
 Net Income From Continuing Operations 75.0 M
EARNINGS
 EPS Estimate 1.30
 EPS Actual 1.55
 EPS Difference 0.25
 EPS Surprise 19.231 %
 Forward EPS 1.58
 
BALANCE SHEET ASSETS
 Total Assets 2.4 B
 Intangible Assets 928.4 M
 Net Tangible Assets 383.4 M
 Total Current Assets 1.0 B
 Cash and Short-Term Investments 593.3 M
 Cash 593.3 M
 Net Receivables 352.9 M
 Inventory 57.6 M
 Long-Term Investments 59.7 M
LIABILITIES
 Accounts Payable 48.1 M
 Short-Term Debt 697.0 K
 Total Current Liabilities 335.7 M
 Net Debt
 Total Debt 625.0 M
 Total Liabilities 1.1 B
EQUITY
 Total Equity 1.3 B
 Retained Earnings 873.0 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 20.10
 Shares Outstanding 65.265 M
 Revenue Per-Share 5.95
VALUATION
 Market Capitalization 6.5 B
 Enterprise Value 6.5 B
 Enterprise Multiple 53.921
Enterprise Multiple QoQ 90.575 %
Enterprise Multiple YoY 43.947 %
Enterprise Multiple IPRWA high: 418.578
mean: 65.943
median: 55.135
LNTH: 53.921
low: -170.556
 EV/R 16.852
CAPITAL STRUCTURE
 Asset To Equity 1.841
 Asset To Liability 2.189
 Debt To Capital 0.323
 Debt To Assets 0.259
Debt To Assets QoQ -2.94 %
Debt To Assets YoY -11.019 %
Debt To Assets IPRWA high: 1.174
median: 0.301
mean: 0.287
LNTH: 0.259
low: 0.018
 Debt To Equity 0.476
Debt To Equity QoQ -7.701 %
Debt To Equity YoY -9.685 %
Debt To Equity IPRWA high: 1.558
median: 0.565
LNTH: 0.476
mean: 0.452
low: -0.505
PRICE-BASED VALUATION
 Price To Book (P/B) 4.963
Price To Book QoQ 18.49 %
Price To Book YoY 23.863 %
Price To Book IPRWA high: 21.577
mean: 5.476
LNTH: 4.963
median: 2.286
low: -4.924
 Price To Earnings (P/E) 64.354
Price To Earnings QoQ 48.458 %
Price To Earnings YoY -9.458 %
Price To Earnings IPRWA high: 344.308
mean: 69.346
LNTH: 64.354
median: 53.373
low: -330.559
 PE/G Ratio 10.44
 Price To Sales (P/S) 16.771
Price To Sales QoQ 24.632 %
Price To Sales YoY 35.62 %
Price To Sales IPRWA high: 66.384
mean: 22.641
LNTH: 16.771
median: 14.212
low: 0.867
FORWARD MULTIPLES
Forward P/E 59.703
Forward PE/G 9.686
Forward P/S 48.892
EFFICIENCY OPERATIONAL
 Operating Leverage -13.488
ASSET & SALES
 Asset Turnover Ratio 0.163
Asset Turnover Ratio QoQ -1.17 %
Asset Turnover Ratio YoY -10.041 %
Asset Turnover Ratio IPRWA high: 0.581
mean: 0.196
median: 0.171
LNTH: 0.163
low: 0.001
 Receivables Turnover 1.096
Receivables Turnover Ratio QoQ 3.71 %
Receivables Turnover Ratio YoY -0.684 %
Receivables Turnover Ratio IPRWA high: 3.342
mean: 1.624
median: 1.509
LNTH: 1.096
low: 0.261
 Inventory Turnover 2.462
Inventory Turnover Ratio QoQ 5.929 %
Inventory Turnover Ratio YoY 17.911 %
Inventory Turnover Ratio IPRWA LNTH: 2.462
high: 2.095
mean: 0.807
median: 0.699
low: 0.055
 Days Sales Outstanding (DSO) 83.28
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 91.042
Cash Conversion Cycle Days QoQ -5.762 %
Cash Conversion Cycle Days YoY -7.182 %
Cash Conversion Cycle Days IPRWA high: 355.423
mean: 133.016
median: 119.382
LNTH: 91.042
low: -70.443
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.561
 CapEx To Revenue -0.006
 CapEx To Depreciation -0.103
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 1.9 B
 Net Invested Capital 1.9 B
 Invested Capital 1.9 B
 Net Tangible Assets 383.4 M
 Net Working Capital 691.4 M
LIQUIDITY
 Cash Ratio 1.767
 Current Ratio 3.06
Current Ratio QoQ 8.181 %
Current Ratio YoY -28.682 %
Current Ratio IPRWA high: 11.702
LNTH: 3.06
mean: 2.511
median: 2.126
low: 0.413
 Quick Ratio 2.888
Quick Ratio QoQ 9.23 %
Quick Ratio YoY -29.007 %
Quick Ratio IPRWA high: 11.177
LNTH: 2.888
mean: 1.984
median: 1.616
low: 0.336
COVERAGE & LEVERAGE
 Debt To EBITDA 5.151
 Cost Of Debt 0.629 %
 Interest Coverage Ratio 20.09
Interest Coverage Ratio QoQ -39.408 %
Interest Coverage Ratio YoY -9.735 %
Interest Coverage Ratio IPRWA high: 70.269
LNTH: 20.09
median: 11.42
mean: 4.913
low: -88.121
 Operating Cash Flow Ratio 0.317
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 29.288
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 2.901 %
 Revenue Growth 2.875 %
Revenue Growth QoQ -139.71 %
Revenue Growth YoY 102.893 %
Revenue Growth IPRWA high: 28.183 %
median: 8.761 %
mean: 8.532 %
LNTH: 2.875 %
low: -6.025 %
 Earnings Growth 6.164 %
Earnings Growth QoQ -20.812 %
Earnings Growth YoY -37.128 %
Earnings Growth IPRWA high: 200.0 %
mean: 19.956 %
median: 8.824 %
LNTH: 6.164 %
low: -81.25 %
MARGINS
 Gross Margin 62.305 %
Gross Margin QoQ 1.809 %
Gross Margin YoY -2.27 %
Gross Margin IPRWA high: 89.754 %
median: 64.456 %
LNTH: 62.305 %
mean: 59.914 %
low: 31.392 %
 EBIT Margin 25.437 %
EBIT Margin QoQ -40.483 %
EBIT Margin YoY -12.126 %
EBIT Margin IPRWA high: 35.132 %
LNTH: 25.437 %
median: 20.496 %
mean: 13.237 %
low: -67.441 %
 Return On Sales (ROS) 25.817 %
Return On Sales QoQ 19.784 %
Return On Sales YoY 10.95 %
Return On Sales IPRWA high: 34.98 %
LNTH: 25.817 %
median: 20.526 %
mean: 12.936 %
low: -86.026 %
CASH FLOW
 Free Cash Flow (FCF) 89.9 M
 Free Cash Flow Yield 1.38 %
Free Cash Flow Yield QoQ -42.524 %
Free Cash Flow Yield YoY -12.492 %
Free Cash Flow Yield IPRWA high: 7.0 %
LNTH: 1.38 %
median: 1.058 %
mean: 0.998 %
low: -8.727 %
 Free Cash Growth -26.278 %
Free Cash Growth QoQ -152.795 %
Free Cash Growth YoY 3.432 %
Free Cash Growth IPRWA high: 776.0 %
mean: 34.178 %
median: -9.348 %
LNTH: -26.278 %
low: -919.099 %
 Free Cash To Net Income 1.198
 Cash Flow Margin 27.413 %
 Cash Flow To Earnings 1.418
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 3.152 %
Return On Assets QoQ -39.127 %
Return On Assets YoY -16.525 %
Return On Assets IPRWA high: 10.633 %
LNTH: 3.152 %
mean: 1.88 %
median: 1.348 %
low: -18.798 %
 Return On Capital Employed (ROCE) 4.749 %
 Return On Equity (ROE) 0.057
Return On Equity QoQ -41.441 %
Return On Equity YoY -15.259 %
Return On Equity IPRWA high: 0.539
mean: 0.063
LNTH: 0.057
median: 0.025
low: -0.544
 DuPont ROE 5.945 %
 Return On Invested Capital (ROIC) 4.194 %
Return On Invested Capital QoQ -38.765 %
Return On Invested Capital YoY -11.78 %
Return On Invested Capital IPRWA high: 13.429 %
LNTH: 4.194 %
mean: 2.98 %
median: 1.784 %
low: -12.224 %

Six-Week Outlook

Technical indicators suggest a period of consolidation or modest downside pressure: declining MACD, a DI/ADX configuration favoring sellers, and RSI rolling down from mid-range. Short-term support clusters lie near the lower Bollinger region and the Ichimoku Senkou B (~$95.93), while the 200-day average (~$80.71) represents a longer-range structural support band. Fundamental drivers over the next six weeks include commercial rollout milestones for PYLARIFY TruVu and any material updates tied to the announced strategic transaction; absence of fresh upside catalysts alongside stretched multiples points to limited immediate upside and a higher probability of rangebound-to-downward price action while liquidity and margin data provide a partial fundamental cushion.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products to aid clinicians in diagnosing and treating cardiovascular, oncological, and other diseases globally. The company provides DEFINITY, an injectable ultrasound enhancing agent for echocardiography exams, and TechneLite, a technetium generator for nuclear medicine procedures. It also offers Xenon-133, a radiopharmaceutical gas for pulmonary function assessment, and Neurolite, an imaging agent for identifying brain blood flow disruptions due to stroke. Lantheus Holdings offers Cardiolite, an imaging agent for assessing cardiac blood flow, and PYLARIFY, a PET imaging agent targeting PSMA-positive lesions in prostate cancer patients. Their portfolio includes the Automated Bone Scan Index for prostate cancer burden calculation and RELISTOR for opioid-induced constipation. Additionally, the company provides aPROMISE and PYLARIFY AI, AI-based medical device software for prostate cancer imaging assessment. The company develops products like 1095, a PSMA-targeted therapy, PNT2002 for mCRPC, and MK-6240, a PET imaging agent targeting Tau tangles in Alzheimer’s disease. Lantheus collaborates with GE Healthcare, NanoMab Technology, and others. Founded in 1956, the company is headquartered in Bedford, Massachusetts.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.